Myungmoon Pharm
명문제약 · 017180
Health Care Pharmaceuticals · KOSPI
Market cap US$34.1M (₩47B)
Overview
Myungmoon Pharm makes finished and active-ingredient medicines, the drugs themselves and the raw pharmaceutical compounds used to produce them, which it supplies to the domestic South Korean market and exports abroad.
It is listed on KOSPI, Korea's main stock exchange. The business operates in two segments: a pharmaceuticals and biotech division, which generates the large majority of revenue, and a services division covering golf-course and real-estate development. Its research pipeline includes generic medicines and improved reformulations of existing drugs, such as a treatment targeting high cholesterol.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$122.9M
- FY2024US$135.1M
- FY2025US$141.5M
Operating profit
- FY2023US$698.4K
- FY2024US$1.4M
- FY2025US$5M
Net income
- FY2023−US$3.5M
- FY2024−US$2.7M
- FY2025US$1M
Key ratios (FY2025)
Why it matters
The consolidated group includes a subsidiary, Myungmoon Bio, focused on pharmaceuticals, and a separate entity, Myungmoon Investment Development, running the non-pharma services business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?